Maxim Group Downgrades TrovaGene (TROV) to Hold; Capital Raise Needed
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/11/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts TROV Hot Sheet
Price: $1.19 --0%
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
7 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Maxim Group downgraded TrovaGene (NASDAQ: TROV) from Buy to Hold.
Analyst Jason Kolbert said the company needs to raise capital. Once raised it will be in a stronger position to transition to a therapeutics company focused on PCM-075.
For an analyst ratings summary and ratings history on TrovaGene click here. For more ratings news on TrovaGene click here.
Shares of TrovaGene closed at $0.68 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA Securities Downgrades Alignment Healthcare Inc (ALHC) to Neutral
- Amrize Ltd (AMRZ) PT Lowered to $32 at RBC Capital
- Bernstein SocGen: 'MediaTek Inc. (2454:TT) (MDTKF) is our Top Pick and the recent pullback provides a good setup'
Create E-mail Alert Related Categories
Analyst Comments, DowngradesRelated Entities
Maxim GroupSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
